![]() ![]() The major drawback of these trials in the present scenario is that majority of patients had not been previously exposed to Rituximab. This allowed more number of patients to undergo ASCT and improved the progression-free survival (PFS), disease-free survival, and overall survival (OS). Addition of Rituximab improved the response rates. Encouraged with these results, Rituximab was added to almost every salvage regimen available. Rituximab monotherapy yielded good results in RR DLBCL. Rituximab with CHOP is the widely accepted first line regimen for the management of DLBCL. The de novo DLBCLs have better prognosis than the latter group. The GCB DLBCL has better response rate than ABC DLBCL.ĭLBCL could present de novo or as a histologic transformation of other low-grade B cell lymphomas like follicular or chronic lymphocytic leukemia/small lymphocytic lymphoma. These differ in the postulated stage of cell of origin, gene expression, and response to anthracycline-based chemotherapy. Using gene-expression profiling, cell-of-origin studies suggested that there are at least 3 distinct subtypes of DLBCL: Activated B-cell (ABC), germinal center B-cell (GCB), and primary mediastinal DLBCL. DLBCL Not Otherwise Specified (NOS) is the commonest variety. In the recent 2008 WHO classification, DLBCL is classified under the diagnostic heading of “mature B cell neoplasms.” DLBCL is a distinct group in itself with many subtypes and entities based on morphology, immunophenotypic characteristics, and clinical presentation. They constitute about 30 to 40% of adult NHLs.ĭiffuse large B cell by definition is a large transformed B cell with nuclear diameter more than twice that of a normal lymphocyte. Diffuse large B cell lymphomas (DLBCLs) are the commonest subtype of NHL. Non-Hodgkin lymphoma (NHL) is the seventh most common malignancy. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |